Vanguard reports 3.10M-share (5.05%) stake in Twist Bioscience (NASDAQ: TWST)
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary
Vanguard Capital Management reported beneficial ownership of 3,101,909 shares of Twist Bioscience Corp common stock, representing 5.05% of the class.
The filing (Schedule 13G) shows sole dispositive power over 3,101,909 shares and sole voting power for 462,865 shares. The report lists the issuer CUSIP 90184D100 and is signed by Ashley Grim on 04/30/2026.
Positive
- None.
Negative
- None.
Key Figures
Beneficial ownership: 3,101,909 shares
Percent of class: 5.05%
Sole voting power: 462,865 shares
+3 more
6 metrics
Beneficial ownership
3,101,909 shares
Amount beneficially owned reported in Item 4
Percent of class
5.05%
Percent of common stock as reported in Item 4
Sole voting power
462,865 shares
Number with sole power to vote reported in Item 4(c)(i)
Sole dispositive power
3,101,909 shares
Number with sole power to dispose reported in Item 4(c)(iii)
Report signature date
04/30/2026
Signature date at end of filing
CUSIP
90184D100
Issuer CUSIP listed in Item 2(d)
Key Terms
Schedule 13G, beneficially owned, sole dispositive power, Investment Company Act
4 terms
Schedule 13G regulatory
"The filing (Schedule 13G) shows sole dispositive power"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
beneficially owned financial
"Amount beneficially owned: 3101909"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole dispositive power regulatory
"Sole power to dispose or to direct the disposition of: 3101909"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Investment Company Act regulatory
"investment companies registered under the Investment Company Act of 1940"
The Investment Company Act is a law that sets rules for businesses whose main activity is managing and selling pooled money, such as mutual funds and other investment funds. It matters to investors because it requires clear reporting, limits managers from putting their own interests ahead of clients, and mandates safekeeping and oversight of assets—similar to safety inspections and traffic rules that help keep shared vehicles reliable and trustworthy.
FAQ
What stake does Vanguard Capital Management report in TWST?
Vanguard Capital Management reports beneficial ownership of 3,101,909 shares, equal to 5.05% of Twist Bioscience Corp's common stock. The figure is reported on a Schedule 13G and appears in the filing's Item 4 ownership section.
When was the Schedule 13G for TWST signed and who signed it?
The Schedule 13G excerpt is signed by Ashley Grim, titled Head of Global Fund Administration, with a signature date of 04/30/2026. The issuer and filer addresses appear in Item 1 and Item 2.
Is the reported ownership held on behalf of other Vanguard entities?
Yes. The filing states ownership reflects securities held by Vanguard Capital Management LLC and affiliates, including Vanguard Asset Management Limited and Vanguard Global Advisers, LLC, and includes securities held by Vanguard funds.
What identifying details are in the filing for Twist Bioscience Corp?
The filing lists the issuer as Twist Bioscience Corp, principal executive office at 681 Gateway Boulevard, San Francisco, CA, and CUSIP 90184D100, with the report focused on common stock.